Reneo Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(In thousands)
| Six Months EndedJune 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(13,787) | $(34,638) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 2,067 | 2,364 |
| Depreciation and amortization | 28 | 83 |
| Amortization/accretion on short-term investments | (1,644) | (2,011) |
| Changes in the fair value of performance award | 1 | 847 |
| Non-cash lease expense | 129 | 241 |
| Loss on disposal of fixed asset | 27 | 3 |
| Changes in operating assets and liabilities: | ||
| Prepaid and other assets | 2,360 | 1,542 |
| Accounts payable and accrued expenses | (16,829) | 6,690 |
| Operating lease liabilities | (173) | (283) |
| Net cash used in operating activities | (27,821) | (25,162) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (2) | (177) |
| Purchase of available-for-sale short-term investments | (67,750) | (132,327) |
| Proceeds from maturities of available-for-sale short-term investments | 104,000 | 82,000 |
| Net cash provided by (used in) investing activities | 36,248 | (50,504) |
| Cash flows from financing activities | ||
| Payments of deferred costs in connection with private placement transaction | (89) | — |
| Proceeds from public offering of common stock, net of offering costs | — | 58,862 |
| Proceeds from private placement of common stock, net of offering costs | — | 4,667 |
| Proceeds from issuance of common stock under the at-the-market facility, net of offering costs | — | 1,009 |
| Proceeds from issuance of common stock in connection with equity plans | — | 282 |
| Net cash (used in) provided by financing activities | (89) | 64,820 |
| Net increase (decrease) in cash and cash equivalents | 8,338 | (10,846) |
| Cash and cash equivalents, beginning of period | 27,632 | 19,927 |
| Cash and cash equivalents, end of period | $35,970 | $9,081 |
| Noncash investing and financing activities: | ||
| Property and equipment in accounts payable | $— | $10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.